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Background: Proton resonance frequency shift (PRFS) magnetic resonance (MR) thermometry exploits the local
magnetic field changes induced by the temperature dependence of the electron screening constant of water
protons. Any other local magnetic field changes will therefore translate into incorrect temperature readings and
need to be considered accordingly. Here, we investigated the susceptibility changes induced by the inflow and
presence of a paramagnetic MR contrast agent and their implications on PRFS thermometry.
Methods: Phantom measurements were performed to demonstrate the effect of sudden gadopentetate
dimeglumine (Gd-DTPA) inflow on the phase shift measured using a PRFS thermometry sequence on a clinical 3 T
magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) system. By proton nuclear magnetic
resonance spectroscopy, the temperature dependence of the Gd-DTPA susceptibility was measured, as well as the
effect of liposomal encapsulation and release on the bulk magnetic susceptibility of Gd-DTPA. In vivo studies were
carried out to measure the temperature error induced in a rat hind leg muscle upon intravenous Gd-DTPA
injection.
Results: The phantom study showed a significant phase shift inside the phantom of 0.6 ± 0.2 radians (mean ± standard
deviation) upon Gd-DTPA injection (1.0 mM, clinically relevant amount). A Gd-DTPA-induced magnetic susceptibility shift
of ΔχGd-DTPA = 0.109 ppm/mM was measured in a cylinder parallel to the main magnetic field at 37°C. The temperature
dependence of the susceptibility shift showed dΔχGd-DTPA/dT = −0.00038 ± 0.00008 ppm/mM/°C. No additional
susceptibility effect was measured upon Gd release from paramagnetic liposomes. In vivo, intravenous Gd-DTPA injection
resulted in a perceived temperature change of 2.0°C ± 0.1°C at the center of the hind leg muscle.
Conclusions: The use of a paramagnetic MR contrast agent prior to MR-HIFU treatment may influence the
accuracy of the PRFS MR thermometry. Depending on the treatment workflow, Gd-induced temperature errors
ranging between −4°C and +3°C can be expected. Longer waiting time between contrast agent injection and
treatment, as well as shortening the ablation duration by increasing the sonication power, will minimize the Gd
influence. Compensation for the phase changes induced by the changing Gd presence is difficult as the
magnetic field changes are arising nonlocally in the surroundings of the susceptibility change.
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Magnetic resonance-guided high-intensity focused ultra-
sound (MR-HIFU) is gaining interest as a noninvasive
method for thermal therapies ranging from local tumor
hyperthermia to thermal ablation. In these procedures,
MRI is used for planning of the HIFU treatment as well
as to dynamically map HIFU-induced temperature
changes [1,2]. Accurate temperature feedback to the
ultrasound control unit is a prerequisite to obtain mild
tumor hyperthermia over a prolonged period of time, as
well as for safety and to provide thermal dose feedback
on the tumor coverage during ablation treatment [3].
Several MR temperature monitoring techniques have
been proposed [4], of which proton resonance frequency
shift (PRFS) thermometry is by far the most commonly
used in water-containing tissues [5]. The frequency shift
arises from the influence of temperature on the hydro-
gen bonds between molecules, resulting in a change in
the electronic screening of the hydrogen nuclei and
therefore the local magnetic field the nuclei experiences
[4,6]. Over the temperature range of interest for HIFU
therapy, the resulting water proton chemical shift is
linearly related to the temperature change with an aver-
age value of −0.01 ppm/°C [4,7,8].
The temperature-induced frequency shift is measured
by the subtraction of gradient-echo phase images ac-
quired before and during heating. As only a change in
frequency is measured using the subtraction method,
PRFS thermometry measures temperature differences ra-
ther than absolute temperatures. Consequently, PRFS
thermometry is also sensitive to magnetic field changes
of other origin than temperature changes alone [9,10].
Examples of magnetic field changes are drift of the
scanner's main magnetic field and field changes caused
by changes in the volume magnetic susceptibility distri-
bution inside the subject. The influence of field drift on
PRFS thermometry has been widely recognized and can
be corrected for by making use of, e.g., a reference re-
gion in which no heating is applied [11]. Magnetic sus-
ceptibility changes can have various origins. They can,
for example, arise from the heating of fat tissue as de-
scribed by Sprinkhuizen et al. [10,12] or from motion
[13]. The demagnetizing effects caused by objects made
of a material with a susceptibility different from that of
the tissue depend on the shape, i.e., cylinder or sphere,
and orientation, i.e., parallel or perpendicular to the
main magnetic field, of the object and have been exten-
sively described in the literature [14]. The presence of
paramagnetic substances, like MRI contrast agents, also
has a strong influence on the magnetic susceptibility. Up
to now, the effect of a paramagnetic MRI contrast agent
in the tissue on PRFS temperature mapping has not yet
been investigated. This effect can be twofold. It can ori-
ginate, first, from a changing distribution of theparamagnetic contrast agent during PRFS thermometry
and, second, from a potential difference in the
temperature dependency of the susceptibility of the con-
trast agent and the tissue.
In MR-HIFU applications, MR contrast agents based
on the paramagnetic gadolinium ion (Gd-CA) are com-
monly used, for example, for tumor delineation during
treatment planning and for measuring treatment re-
sponse [15,16]. Another example is the use of Gd agents
encapsulated in temperature-sensitive drug delivery car-
riers (paramagnetic liposomes) to monitor liposomal
content release [17,18]. However, paramagnetic contrast
agents such as Gd-CA have a volume magnetic suscepti-
bility that differs considerably from that of the tissue. In
the literature, susceptibility-induced frequency shifts, Δχ,
of 0.32 ppm/mM for gadopentetate dimeglumine (Gd-
DTPA) have been reported. The final effect depends on
the geometrical distribution of the contrast agent with
respect to the main magnetic field [19-21]. In the clinical
practice of contrast-enhanced MRI, local tissue gadolin-
ium concentrations in the low millimolar range are not
unusual [22]. The phase differences between images ac-
quired before and during heating with PRFS thermom-
etry will therefore depend not only on the temperature
changes but also on changes in the distribution of the
Gd agent. As a consequence, PRFS temperature mapping
in the presence of gadolinium-containing contrast agents
could, without taking proper precautions, lead to local
temperature errors of several tens of degrees.
We performed a set of in vitro and in vivo experiments
to measure the effects of Gd-DTPA (MAGNEVISTW,
Bayer Schering, Berlin, Germany) on the phase shift mea-
sured by PRFS thermometry in different scenarios. First,
the effects of a changing concentration of Gd-DTPA on
PRFS thermometry were assessed. Next, the temperature
dependence of the paramagnetic susceptibility-induced
frequency shift of Gd-DTPA was investigated in phan-
toms. Finally, we investigated whether the release of Gd-
CA from paramagnetic temperature-sensitive liposomes
had an effect on the bulk magnetic susceptibility.
Materials and methods
Phantom measurements: varying Gd-DTPA concentrations
Phantom measurements were performed to demonstrate
the effect of sudden change in Gd-DTPA concentration
on the phase shift measured using a PRFS thermometry
sequence. A plastic cylindrical container (inner diameter =
0.8 cm, outer diameter = 1.0 cm, height = 4.0 cm)
containing demineralized water (1.25 mL) was aligned
perpendicular to the main magnetic field of a 3 T clinical
MR scanner (Philips AchievaW, Best, the Netherlands).
The container was positioned and fixed inside a water-
tight, HIFU-compatible MR receiver coil placed in a larger
water pool [23]. The temperature of the fluid inside the
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the pool water (T = 21.2°C). Baseline PRFS temperature
mapping was performed for 10 min in the absence of Gd-
DTPA using the same PRFS sequence as used for the
in vivo studies. The sequence was a spoiled gradient echo
sequence with an echo planar imaging (EPI) readout (EPI
factor, 7) and sensitivity encoding (SENSE) (SENSE factor,
1.8; SENSE direction, right to left) to allow fast imaging.
The repetition time (TR) was set to 38 ms with an echo
time (TE) of 20 ms. The rest of the PRFS parameters were
set as follows: field of view (FOV), 250 × 250 mm2; voxel
size, 1.4 × 1.4 × 4.1 mm3; fat suppression, spectral pre-
saturation with inversion recovery (SPIR); number of
averages, 4, resulting in a dynamic scan time of 2.1 s.
One coronal and one transverse slice were continu-
ously acquired, both through the container midpoint.
The evolution of phase φ over time was measured dir-
ectly without further processing. From the phase data,
the corresponding temperature change (ΔT) was calcu-
lated according to [4]
ΔT x; yð Þ ¼ φ x; yð Þ−φ0 x; yð Þ
γαB0TE
; ð1Þ
where φ0 is the baseline phase at the start of the meas-
urement (in radians), γ the hydrogen gyromagnetic ra-
tio (in radians/second/tesla), B0 the main magnetic
field strength (in tesla), and α the temperature coeffi-
cient of the water proton electron screening constant
(−0.01 ppm/°C) [4]. The corresponding temperature
change (i.e., not corrected for the effect caused by a
changing Gd distribution) was calculated after the cor-
rection of the acquired signal for the drift of the main
magnetic field. Therefore, a phase correction was
performed by subtracting the average phase in a refer-
ence region from the acquired phase image. The refer-
ence region was placed inside the water pool, at least 5
cm away from the container.
After baseline measurements were performed, Gd-DTPA
(180 μL of 1:50 diluted MagnevistW, [Gd-DTPA]final = 1.0
mM, 20 μL flush) was added to the container using an in-
fusion pump (injection speed = 1 mL/min). The fluid in
the container was carefully mixed during a period of 1 min
from the start of injection using a Pasteur pipette. Fixation
of the container prevented unintended movement during
mixing. PRFS thermometry was continued for another 10
min, after which the data were exported and processed in
MATLAB (R2010a, MathWorks, Natick, MA, USA). Be-
fore and after PRFS thermometry, a map of the longitu-
dinal relaxation time (T1) was acquired using a steady-state
Look-Locker sequence [24,25] (EPI factor, 5; TR/TE,
9.0:3.4 ms; interval time, 100 ms; flip angle α, 10°; FOV,
50 × 69 mm2; matrix, 64 × 65; fat suppression, SPIR;
slice thickness, 5 mm parallel to the cylinder long axis;number of averages, 2; acquisition time, 2:36 min). The
effective T1 (T1
* ) was calculated from the signal recov-
ery on a voxel-by-voxel basis using an in-house created
IDL-based software tool (IDL version 6.3, RSI, Boulder,
CO, USA). Further data processing was performed in
MATLAB, in which the longitudinal relaxation rate (R1)
was calculated from the effective R1
* (R1
* = 1/T1
* , R1 = R1
* +
ln(cos(α))/TR, with α = 10° and TR = 100 ms [24]) on a
voxel-by-voxel basis.
Phantom measurements: temperature dependence of
susceptibility
As the volume magnetic susceptibility of water-containing
tissues is known to be temperature dependent, the effect
of changing temperature on the water proton shift of a so-
lution containing a stable amount of Gd-DTPA was mea-
sured. The proton shifts were measured at three constant
Gd-DTPA concentrations (0, 3.13, and 4.67 mM) at five
different temperatures (T = 37°C, 41°C, 45°C, 50°C, and
55°C) by proton nuclear magnetic resonance (1H-NMR)
spectroscopy. The Gd-DTPA concentrations were chosen
as they approximate the amount of contrast agent present
in human malignant breast tumor tissue (Fan et al. [22]),
respectively, 30 and 10 min after the injection of the
standard clinical Gd-DTPA dose (0.1 mmol/kg bw). Sam-
ples containing the desired concentration of Gd-DTPA
were prepared by dilution with demineralized water. Five
hundred microliters of sample was transferred into a
standard thin-walled 5-mm-diameter cylindrical NMR
tube (the outer compartment). Before the 1H-NMR meas-
urement, a glass capillary (product number: WGS-5BL,
Wilmad, Vineland, NJ, USA) containing aqueous (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buf-
fer (20 mM, pH 7.5) and 3-(trimethylsilyl)-1-propanesulfonic
acid sodium salt (DSS; 1.1 mM) was inserted coaxially into
the NMR tube (the inner compartment). Standard 1H-NMR
spectra were acquired with 128 k complex data points and a
dwell time of 41.6 μs using a Bruker AVANCE300 NMR
spectrometer (Madison, WI, USA) equipped with a wide-
bore 7-T superconducting magnet (Oxford Instruments,
Abingdon, UK). In order to prevent line broadening as a re-
sult of radiation damping, the 300-MHz RF transmit-
receive circuit was detuned by −4 MHz. The peak
chemical shift positions of the sample (δsample) and ref-
erence (δref ) were determined using a peak picking al-
gorithm. The frequency of the DSS methyl signal
originating from the inner compartment was calibrated
for temperature dependence using δ = −0.071 − 9.9 ×
10−5 T − 5.9 × 10−7 T2 (ppm), T being the sample
temperature (in °C) [26]. The 1H-NMR spectra of the
diamagnetic reference sample showed a single water
signal at a chemical shift moving from 4.6 (37°C) to 4.4
ppm (55°C) upon heating. Apparently, the presence of
the small amounts of DSS and HEPES buffer in the
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ences in the diamagnetic susceptibility. In the para-
magnetic spectra, by contrast, two separate water
signals were observed: (1) a weak signal at the same
frequency as in the corresponding diamagnetic refer-
ence spectrum originating from the water in the dia-
magnetic inner compartment and (2) an intense signal
that shifted approximately 0.3–0.5 ppm towards a
higher frequency originating from the water in the
Gd-DTPA-containing outer compartment (the actual
spectra can be found in Additional file 1). The Gd-
DTPA-induced frequency shift (in ppm) was obtained
from the frequency shift of the water signal between
the two measurements, according to the method
presented by Corsi et al. (Method 1, [21]). Since Gd-
DTPA is not expected to cause a (pseudo)contact shift
of the water signal, the susceptibility-induced fre-
quency shift can alternatively be determined from a
single NMR spectrum as the frequency difference be-
tween the water signals from the paramagnetic and the
diamagnetic compartment (Method 2, [25]). Both
methods gave identical susceptibility shifts within the
experimental error (±0.005 ppm).
In vivo study
The effect of intravenous Gd-DTPA injection on the
phase stability in the rat hind limb muscle was measured
to demonstrate the effect of Gd-DTPA injection during
an in vivo study (Fisher 344 rats, n = 4). All animal stud-
ies were approved by the animal welfare committee of
the Maastricht University (the Netherlands) and were in
compliance with the guidelines set by the institutional
animal care committee, accredited by the National De-
partment of Health.
Ultrasound gel (Aquasonic 100, Parker Laboratories,
Fairfield, NJ, USA) was applied onto the shaven leg to
minimize tissue-air interfaces. The animal was placed
into a dedicated small animal HIFU-compatible MR coil
setup (Philips Healthcare, Vantaa, Finland) [23]. The res-
piration rate of the animals was monitored continuously
using a small balloon sensor (Graseby, Smiths Medical,
St. Paul, MN, USA). The animal body temperature was
monitored using a rectal temperature probe (Neoptix,
Québec City, Canada). The body temperature was kept
stable by running water through a circuitry positioned
below the animal body.
The system stability was assessed by measuring the
phase during a period of 4 min prior to Gd-DTPA injec-
tion. Gd-DTPA (MagnevistW) was injected via a tail vein
catheter using an infusion pump (0.6 mmol/kg bw, 0.5 M,
injection speed, 1 mL/min). This dose is the rat equivalent
of the human clinical Gd-DTPA dose (0.1 mmol/kg bw)
[27]. No HIFU heating was applied. Phase mapping was
continued up to 10 min postinjection. The concentrationof Gd-DTPA in the muscle tissue was quantified based on
the differences in R1 before and directly after the PRFS
measurements. Therefore, R1 maps of the muscle were ac-
quired using the same Look-Locker protocol as described
for the phantom experiments.
Susceptibility of liposomal encapsulated Gd
Finally, we investigated whether there is an effect of lipo-
somal encapsulation and release on the bulk magnetic
susceptibility effect of Gd-CA by 1H-NMR spectroscopy.
Therefore, the BMS shift (Δχ) of a solution containing
paramagnetic temperature-sensitive liposomes (TSLs)
was measured before and after temperature-induced
contrast agent release using the same spectrometer and
method as described in the temperature dependence ex-
periment above. Traditional TSLs were made in-house
using a previously described protocol [28]. The aqueous
lumen of the TSL contained 250 mM [Gd(HPDO3A)
(H2O)] (Prohance
W, Bracco Diagnostics, Milan, Italy). The
final gadolinium concentration of the TSL suspension was
5.3 mM, as determined by inductively coupled plasma-
mass spectrometry (ICP-MS; DRCII, PerkinElmer,
Waltham, MA, USA). Five hundred microliters of the
liposomal suspension was transferred into a standard
thin-walled 5-mm-diameter cylindrical NMR tube (the
outer compartment). Before the 1H-NMR measure-
ment, a glass capillary containing HEPES buffer (20
mM, pH 7.5) and DSS (1.1 mM) was inserted coaxially
into the NMR tube (the inner compartment). The ef-
fect of the diamagnetic species present in the suspen-
sion (phospholipids, sodium chloride, HEPES buffer)
on the magnetic susceptibility was assumed negligible
[29]. The 1H-NMR chemical shift of the water signal
in the outer compartment was measured at T = 37°C
before and after the temperature-induced release of
the encapsulated [Gd(HPDO3A)(H2O)]. Contrast agent re-
lease was effectuated by the heating of the sample to T =
50°C for 90 s inside the magnet using the sample heater of
the NMR spectrometer and checked by measuring the R1
of the sample before and after heating using a standard
spectroscopic inversion recovery NMR sequence (at 37°C).
Inversion-recovery curves (NMR signal intensity versus in-
version recovery time) were calculated from the integrals
of the water signal. Actual R1 values were obtained from
the inversion-recovery curves using the Levenberg-
Marquardt nonlinear least squares fitting procedure of the
Bruker TopSpin NMR software. All inversion-recovery
curves could be fitted with a pure single-exponential decay
function.
Results
Phantom measurements: varying Gd-DTPA concentrations
The effect of a changing amount of Gd-DTPA on the
phase measured with a PRFS-based MR thermometry
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containing phantom kept at a stable temperature. The
phase signal showed a variation over time owing to
drift of the main magnetic field (Figure 1B). After cor-
rection, a stable baseline temperature profile was ob-
served (Figure 1C). Upon Gd-DTPA injection, the
phase signal was heavily disturbed owing to the fast
movement of the water molecules through the imaging
gradients during the mixing of the contrast agent with
the water in the phantom (green bar in Figure 1B,C).
After the phantom fluid had stabilized again, the phase
shifts after injection were compared with pre-injection
and were measured in the middle of the phantom (x0)
and in six points to the left and to the right (x−6 to x+6).
Phase shift values of 0.6 ± 0.2 radians (mean ± standard
deviation (SD)) were observed inside the phantom (x−1 to
x+1) comparing before (t = 250 s) and after Gd injection
(t = 400 s). With the used temperature measurement se-
quence, this translates in a perceived temperature
change inside the cylinder of approximately +3.8°C ±
1.3°C. These temperature changes were within the
range that was expected from theory based on the Gd-
DTPA susceptibility and sample orientation (cylin-
drical sample oriented perpendicular to the main mag-
netic field: ΔχGd-DTPA = 0.32 × (−1/6) = −0.053 ppm/mM,Figure 1 Varying Gd-DTPA concentrations in phantoms. (A) MRI phase
The red scale bar indicates the voxel locations in plots B and C. (B) Phase p
phase image. The green bar indicates the time span during which Gd-DTPA
magnetic field drifts. (C) Plot of the calculated temperature error over time
drifts and was calculated from the magnetic field changes via the −0.01 pp1 mM Gd-DTPA, −0.053 / −0.01 = +5.3°C maximum PRFS
temperature error inside the sample) [30].
Phantom measurements: temperature dependence of
susceptibility
Figure 2 displays the water proton chemical shifts at dif-
ferent Gd concentrations and temperatures. The fre-
quency of the water signal (relative to the inner
compartment DSS reference signal) in the sample
containing demineralized water only (0 mM Gd-DTPA)
changed from approximately 4.6 ppm at 37°C to ap-
proximately 4.4 ppm at 55°C. A standard fitting proced-
ure with a linear model function yielded excellent fits
with a slope of −0.0106 ppm/°C (R2 = 0.9998). Similar
values were previously reported in other studies [4,7,8]
and are generally attributed to temperature-dependent
variations in the electronic screening of the hydrogen
nuclei of water molecules. By subtracting the water pro-
ton shift obtained at each temperature with different
concentrations of Gd-DTPA, the Δχ induced by the
presence of Gd-DTPA and its temperature dependence
were calculated. This resulted in ΔχGd-DTPA = 0.109
ppm/mM at 37°C for a cylinder parallel to the main
magnetic field, closely corresponding to values previ-
ously found for aqueous Gd chelates [21] and valuesimages before and after Gd-DTPA injection. No heating was applied.
lot in which each line indicates the phase over time of a point in the
was injected and mixed. The phase signal was not corrected for main
. The apparent temperature change was corrected for magnet field
m/°C relation [4,8].
Figure 2 The Gd-induced susceptibility effect is temperature
dependent. The water proton frequency shift at different
temperatures in the presence of different Gd-DTPA concentrations.
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main magnetic field, 1/3Δχ, 1/3 × 0.32 ppm/mM = 0.107
ppm/mM, which is close to the measured value) [20,29,31].
The temperature dependence measured in the relatively
narrow temperature range between 37°C and 55°C showed
a linear behavior with dΔχGd-DTPA/dT = −0.00038 ±
0.00008 ppm/mM/°C. More details can be found in
Additional file 1.Figure 3 The effect of Gd injection in vivo. (A) Schematic drawings of th
magnitude image of the rat hind leg as obtained with the PRFS thermome
locations in plot B. (B) The perceived temperature baseline error over time
signal intensity data obtained at x0 indicating the inflow of Gd-DTPA into tIn vivo study
Four animals were injected with Gd-DTPA (0.6 mmol/kg bw)
to measure the magnetic susceptibility effect of a changing
amount of Gd-CA in the tissue on the phase stability of
gradient-echo PRFS images. The animal body temperature
was tightly regulated and kept constant at 37°C ± 0.2°C, as
measured using the rectal temperature probe. In vivo
PRFS thermometry without heating in the absence of a
Gd-based contrast agent showed no average temperature
change over a period of 10 min with a standard deviation
of 0.3°C. Intravenous Gd-DTPA injection resulted in a
change of the local magnetic field, which translated into
an apparent temperature change of −2.0°C ± 0.1°C
(mean ± SD) in the middle of the hind leg muscle (x0
in Figure 3A). Depending on the PRFS voxel location, the
presence of Gd-DTPA in the tissue resulted in either a
positive (central area) or a negative (peripheral area) phase
shift and apparent temperature change (Figure 3B). As
expected based on the literature [14], the susceptibility-
induced shift showed a symmetrical pattern around the
Gd-DTPA-perfused tissue (i.e., x−5 = x+5, x−4 = x+4,
etcetera).
The inflow of Gd-DTPA into the rat hind leg muscle tis-
sue could qualitatively be observed from the magnitude im-
ages obtained with the PRFS sequence (Figure 3C). The
Gd-DTPA inflow showed coincidence with the observed
increase in the perceived temperature error. The amount of
Gd-DTPA present in the muscle tissue was quantitativelye animal orientation in transversal and coronal directions, and a
try sequence (coronal view). The red scale bar indicates the voxel
in vivo over a horizontal line profile in the rat muscle. (C) PRFS voxel
he rat hind leg muscle.
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R1 maps were acquired prior to and immediately after PRFS
thermometry. Ten minutes after injection, a ΔR1 ≈ 0.68 s
−1
was found, indicating that approximately 0.18 mM Gd-
DTPA was present in the muscle tissue (assuming ΔR1 = r1
[CA], with r1 = 3.7 mM
−1 s−1 (3.5–3.9) the Gd-DTPA
relaxivity in plasma at 37°C according to [32]).
Susceptibility of liposomal encapsulated Gd
1H-NMR spectroscopy was performed to investigate
whether the liposomal encapsulation of Gd-CA has an
influence on the magnetic susceptibility. The proton res-
onance frequency of the compartment containing para-
magnetic liposomes was shifted 0.565 ppm towards a
higher frequency compared with the compartment with-
out liposomes. The gadolinium concentration as calcu-
lated from this shift Δχ was 5.35 mM, corresponding to
the concentration as determined by ICP-MS (5.3 mM).
After heating above the liposomal phase transition
temperature, inducing Gd release (ΔR1 ≈ 2 s
−1), the res-
onance frequency of the TSL compartment showed a
minor additional shift of 0.005 ppm upwards (<1% of the
total effect of introducing paramagnetic liposomes).
However, similar shifts (between 0.003 and 0.007 ppm)
were observed after heating and cooling down of a solu-
tion containing [Gd(HPDO3A)(H2O)] only (no lipo-
somes) and after heating and cooling down of pure
water. Therefore, the frequency shift observed upon Gd
release from the liposomes was regarded within the
error of detection.
Discussion
MR-HIFU is increasingly used for noninvasive thermal
therapies ranging from mild hyperthermia to thermal
ablation. Accurate MR thermometry is crucial to per-
form such procedures in a controlled and successful
manner. PRFS thermometry is the most frequently used
MR thermometry method, which uses local nuclear
magnetic field changes to calculate temperature differ-
ences. Subtraction-based PRFS thermometry is sensitive
not only to temperature-induced changes of the elec-
tronic screening of water protons (α ≈ −0.01 ppm/°C),
but also to other magnetic field-influencing effects such
as a Gd-based contrast agent flowing in or out of the
monitored region and the temperature dependency of
the magnetic susceptibility of the tissue with such a con-
trast agent. The latter effects - if active - cause a system-
atic error on the experimental PRFS temperature change
that has been seriously neglected thus far. Here, we dis-
cuss the impact of Gd-DTPA presence on the size and
the direction of the PRFS temperature errors.
In the absence of heating, we measured a Gd-induced
phase shift in the rat hind leg muscle that would errone-
ously be interpreted as a 2° temperature difference. Theseresults nicely corresponded to theory (0.18 mM Gd-
DTPA in muscle tissue, Δχ = 0.18 × 0.109 ppm/mM =
0.02 ppm maximum shift in the case of cylindrically
shaped sample oriented parallel to the main magnetic
field, 0.02 / −0.01 = −2.0°C PRFS temperature error).
However, in most MR-HIFU cases, the temperature
change measurement will not be performed during the
injection of the contrast agent or closely thereafter.
Obviously, the smaller the change in contrast agent
concentration and distribution, the smaller the effect
the contrast agent will have on PRFS temperature
monitoring. The local changes in contrast agent con-
centration over time will differ for different tissue
types, malignant versus benign tumors, and species
(half-life of Gd-DTPA approximately 96 min in
humans [33] compared with 19.6 min in rats [34]).
Therefore, it is advisable to characterize the behavior
and washout of the contrast agent in the area of inter-
est once at the beginning of a new study. Subsequently,
the washout information needs to be taken into con-
sideration when deciding on the final MR-HIFU treat-
ment workflow.
To give an indication of the expected temperature
error range in human breast cancer treatment, the
values measured for human Gd-DTPA clearance rates in
malignant breast tumors as described and modeled by
Fan et al. [22] were used. Based on their model, the con-
trast agent concentration in the tumor was calculated at
different time points after the injection of a standard
clinical Gd-DTPA dose (0.1 mmol/kg bw). The expected
Gd-induced water proton shift was calculated based on
the contrast agent variations in combination with the
measured Gd-DTPA susceptibility (ΔχGd-DTPA = 0.327
ppm/mM at 37°C) and assuming a spherical tumor [30].
With a perfect spherical geometry, no field shift occurs
inside the tumor; however, at the tumor border zone, a
Gd-induced shift can be expected of 2/3ΔχGd-DTPA =
0.218 ppm/mM. Assuming 0.5–3 min per sonication
(i.e., the time that the ultrasound transducer is on, as-
suming a new reference phase map is acquired (φ0) at
the start of each sonication), 30–60 min of waiting
time between the injection of the paramagnetic con-
trast agent and the start of the HIFU treatment, the
Gd-induced temperature error at the tumor edges
ranges between 0°C and −4°C.
In order to minimize this effect of the contrast agent,
it is advised to perform the ablation with a high sonic-
ation power (within the safety limits), so that the time
per sonication is kept as short as possible. Furthermore,
trapping of the contrast agent inside the ablated tissue
owing to local vascular shutdown is likely to further re-
duce the contrast agent change.
The practical implications of the effect caused by the
temperature dependence of the magnetic susceptibility
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ppm/mM/°C, measured in water) are more complicated.
Here, the temperature dependence of the magnetic sus-
ceptibility of Gd-DTPA was measured in water and not
in actual tissue. This is not fully correct considering the
temperature-dependent variations that occur in the tis-
sue density and variations between different tissue types.
Despite this limitation, we observed that with low
amounts (<1 mM) of Gd-DTPA present, the Gd-DTPA
magnetic susceptibility closely follows that of pure water
and glandular tissue [9,10], leading to no significant
changes in the susceptibility distribution upon heating.
However, 30 min after the injection of a standard im-
aging dose of Gd-DTPA, the local amount of Gd-DTPA
in human malignant breast tissue approximates 3 mM
[22], resulting in a local susceptibility temperature de-
pendence of Δχ ≈ −0.0011 ppm/°C. This value is ap-
proximately 10% of that of the electronic screening
constant used for the PRFS temperature measurement.
Thus, even without Gd-DTPA concentration changes,
the susceptibility temperature dependence within the tis-
sue can lead to temperature errors of maximally +3°C in
the tumor, during a temperature increase of ΔT = 30°C.
Errors of this magnitude will influence the accuracy of
the thermal dose calculations and thus the expected
treatment success. The effect induced by the Gd pres-
ence will be retained longer by the slower clearance of
the Gd-DTPA owing to the tissue ablation.
Accurate temperature measurements to allow feedback
control of the power emitted by the HIFU transducer is
also essential to obtain prolonged MR-HIFU-induced
hyperthermia, e.g., required for temperature-induced
drug delivery (≈30 min at 41°C). Noninvasive MR im-
aging and quantification of the HIFU hyperthermia-
induced drug delivery process has been demonstrated
using paramagnetic TSLs co-encapsulating drugs and
MRI contrast agents [17,18,35-37]. In this process, the
contrast agent is released from the liposomes during
heating. Liposomal encapsulation lowers the relaxivity of
the Gd-CA owing to reduced water exchange over the li-
posomal membrane. Upon heating above the liposomal
phase transition temperature, the normal relaxivity of
the contrast agent is retrieved as water access is re-
stored. The Gd-induced bulk magnetic susceptibility ef-
fect, however, occurs at a more macroscopic scale. We
measured whether the bulk magnetic susceptibility
changes upon the release of the contrast agent from the
liposomes. A frequency difference of 0.565 ppm was ob-
served between the signal originating from pure water
and the signal coming from the paramagnetic liposomes.
Upon heating and release, an additional frequency in-
crease of 0.005 ppm was observed (<1%); however, this
shift was also observed after the heating of free Gd-
DTPA or pure water, indicating that there was no effectof Gd release from the paramagnetic liposomes itself upon
the bulk magnetic susceptibility. Although the Gd release
in itself does not cause an additional susceptibility effect,
it is crucial in the MR-HIFU hyperthermia-induced drug
delivery workflow to perform the paramagnetic liposome
injection prior to the acquisition of the reference phase
scan (φ0), which is at the onset of PRFS thermometry. The
long blood circulation time (≈2 h) of the paramagnetic li-
posomes is beneficial as the Gd concentration in the blood
will not change as rapid as it does after the injection of
un-encapsulated Gd-DTPA.
Conclusion
Using a paramagnetic contrast agent during MR-HIFU
treatments has the advantage to better delineate the ab-
lation target region or to show the release of drug from
temperature-sensitive liposomes, but has the disadvan-
tage to influence the accuracy of the PRFS thermometry.
Owing to the contrast agent injection, the temperature
change calculated based on the phase change becomes a
function of the variation in spatial temperature distribu-
tion and of the local Gd concentration. Depending on
the treatment workflow, Gd-induced temperature errors
ranging between −4°C and +3°C can be expected. These
errors originate not only from the change in Gd concentra-
tion, but also from the different susceptibility temperature
dependence of the tissue with and without Gd. Longer
waiting time between contrast agent injection and HIFU
treatment, as well as shortening the ablation duration by
increasing the sonication power, will minimize the Gd in-
fluence. Compensation for the phase changes induced by
the changing Gd presence is difficult as the magnetic field
changes are arising both locally and nonlocally in the sur-
roundings of the susceptibility change.
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